Q2 2021 EPS Estimates for AVITA Medical, Inc. Lowered by Analyst (NASDAQ:RCEL)


Share on StockTwits

AVITA Medical, Inc. (NASDAQ:RCEL) – Oppenheimer cut their Q2 2021 EPS estimates for AVITA Medical in a research report issued on Monday, January 11th. Oppenheimer analyst K. Degeeter now anticipates that the company will earn ($0.45) per share for the quarter, down from their previous estimate of ($0.35). Oppenheimer also issued estimates for AVITA Medical’s FY2021 earnings at ($1.68) EPS and FY2022 earnings at ($1.36) EPS.

RCEL has been the topic of several other research reports. BidaskClub upgraded AVITA Medical from a “strong sell” rating to a “sell” rating in a report on Friday, December 25th. ValuEngine upgraded AVITA Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 5th. Finally, Zacks Investment Research downgraded AVITA Medical from a “hold” rating to a “sell” rating in a report on Wednesday, October 28th. Two investment analysts have rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $33.20.

RCEL opened at $20.51 on Thursday. The company has a market cap of $443.49 million, a P/E ratio of -9.91 and a beta of 1.15. The business’s 50-day moving average price is $19.71 and its 200-day moving average price is $23.09. AVITA Medical has a 12 month low of $16.87 and a 12 month high of $55.35.

AVITA Medical (NASDAQ:RCEL) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.23). The firm had revenue of $5.06 million for the quarter, compared to the consensus estimate of $5.70 million.

A number of large investors have recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC grew its position in AVITA Medical by 19.8% in the third quarter. Steward Partners Investment Advisory LLC now owns 3,904 shares of the company’s stock valued at $98,000 after purchasing an additional 645 shares in the last quarter. Financial Consulate Inc. grew its stake in AVITA Medical by 5.9% in the 3rd quarter. Financial Consulate Inc. now owns 10,848 shares of the company’s stock valued at $273,000 after buying an additional 600 shares during the last quarter. LPL Financial LLC lifted its position in AVITA Medical by 20.4% during the third quarter. LPL Financial LLC now owns 11,515 shares of the company’s stock worth $290,000 after acquiring an additional 1,950 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of AVITA Medical during the second quarter worth approximately $441,000. Finally, Advisors Asset Management Inc. lifted its holdings in AVITA Medical by 285.0% during the 3rd quarter. Advisors Asset Management Inc. now owns 18,311 shares of the company’s stock worth $461,000 after purchasing an additional 13,555 shares during the last quarter. Hedge funds and other institutional investors own 6.64% of the company’s stock.

AVITA Medical Company Profile

AVITA Medical Inc operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo.

Recommended Story: Inverted Yield Curve

Earnings History and Estimates for AVITA Medical (NASDAQ:RCEL)

Receive News & Ratings for AVITA Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA Medical and related companies with MarketBeat.com's FREE daily email newsletter.